Cronos Group Inc (TSE:CRON) has received a consensus recommendation of “Hold” from the nine brokerages that are covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is C$19.44.
A number of brokerages recently issued reports on CRON. Jefferies Financial Group lowered their price target on shares of Cronos Group from C$15.00 to C$10.00 in a research report on Friday. BMO Capital Markets raised shares of Cronos Group from an “underperform” rating to a “market perform” rating and set a C$16.00 price target for the company in a research report on Thursday, September 5th. CIBC lowered their price target on shares of Cronos Group from C$25.00 to C$20.00 in a research report on Friday, October 4th. Canaccord Genuity raised shares of Cronos Group from a “sell” rating to a “hold” rating and lifted their price target for the company from C$16.00 to C$17.00 in a research report on Friday, August 9th. Finally, Cowen lowered their price target on shares of Cronos Group from C$21.00 to C$17.00 in a research report on Tuesday, September 3rd.
TSE CRON traded down C$0.21 during trading hours on Wednesday, reaching C$10.37. 716,000 shares of the company’s stock traded hands, compared to its average volume of 1,527,942. Cronos Group has a 52-week low of C$8.47 and a 52-week high of C$32.95. The firm has a market cap of $3.49 billion and a PE ratio of 14.59. The firm has a 50-day simple moving average of C$13.79 and a 200 day simple moving average of C$19.02. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.68 and a quick ratio of 1.64.
About Cronos Group
Cronos Group Inc, formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations MMPR. The firm typically invests in companies based in Canada.
Recommended Story: Average Daily Trade Volume – What It Means In Stock Trading
Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.